Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.
Identifieur interne : 000678 ( PubMed/Corpus ); précédent : 000677; suivant : 000679Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.
Auteurs : P. De Deurwaerdère ; M. Lagière ; M. Bosc ; S. NavaillesSource :
- Experimental brain research [ 1432-1106 ] ; 2013.
English descriptors
- KwdEn :
- Animals, Basal Ganglia (metabolism), Humans, Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Receptor, Serotonin, 5-HT2C (metabolism), Schizophrenia (metabolism), Schizophrenia (physiopathology), Serotonin (metabolism), Substance-Related Disorders (metabolism), Substance-Related Disorders (physiopathology).
- MESH :
- chemical , metabolism : Receptor, Serotonin, 5-HT2C, Serotonin.
- metabolism : Basal Ganglia, Parkinson Disease, Schizophrenia, Substance-Related Disorders.
- physiopathology : Parkinson Disease, Schizophrenia, Substance-Related Disorders.
- Animals, Humans.
Abstract
Serotonin2C (5-HT2C) receptors are expressed in the basal ganglia, a group of subcortical structures involved in the control of motor behaviour, mood and cognition. These receptors are mediating the effects of 5-HT throughout different brain areas via projections originating from midbrain raphe nuclei. A growing interest has been focusing on the function of 5-HT2C receptors in the basal ganglia because they may be involved in various diseases of basal ganglia function notably those associated with chronic impairment of dopaminergic transmission. 5-HT2C receptors act on numerous types of neurons in the basal ganglia, including dopaminergic, GABAergic, glutamatergic or cholinergic cells. Perhaps inherent to their peculiar molecular properties, the modality of controls exerted by 5-HT2C receptors over these cell populations can be phasic, tonic (dependent on the 5-HT tone) or constitutive (a spontaneous activity without the presence of the ligand). These controls are functionally organized in the basal ganglia: they are mainly localized in the input structures and preferentially distributed in the limbic/associative territories of the basal ganglia. The nature of these controls is modified in neuropsychiatric conditions such as Parkinson's disease, tardive dyskinesia or addiction. Most of the available data indicate that the function of 5-HT2C receptor is enhanced in cases of chronic alterations of dopamine neurotransmission. The review illustrates that 5-HT2C receptors play a role in maintaining continuous controls over the basal ganglia via multiple diverse actions. We will discuss their interest for treatments aimed at ameliorating current pharmacotherapies in schizophrenia, Parkinson's disease or drugs abuse.
DOI: 10.1007/s00221-013-3508-2
PubMed: 23615975
Links to Exploration step
pubmed:23615975Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.</title><author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name><affiliation><nlm:affiliation>Université de Bordeaux, Bordeaux Cedex, France, deurwaer@u-bordeaux2.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M" last="Lagière">M. Lagière</name></author><author><name sortKey="Bosc, M" sort="Bosc, M" uniqKey="Bosc M" first="M" last="Bosc">M. Bosc</name></author><author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23615975</idno><idno type="pmid">23615975</idno><idno type="doi">10.1007/s00221-013-3508-2</idno><idno type="wicri:Area/PubMed/Corpus">000678</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000678</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.</title><author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name><affiliation><nlm:affiliation>Université de Bordeaux, Bordeaux Cedex, France, deurwaer@u-bordeaux2.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M" last="Lagière">M. Lagière</name></author><author><name sortKey="Bosc, M" sort="Bosc, M" uniqKey="Bosc M" first="M" last="Bosc">M. Bosc</name></author><author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name></author></analytic><series><title level="j">Experimental brain research</title><idno type="eISSN">1432-1106</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Basal Ganglia (metabolism)</term><term>Humans</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (physiopathology)</term><term>Receptor, Serotonin, 5-HT2C (metabolism)</term><term>Schizophrenia (metabolism)</term><term>Schizophrenia (physiopathology)</term><term>Serotonin (metabolism)</term><term>Substance-Related Disorders (metabolism)</term><term>Substance-Related Disorders (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptor, Serotonin, 5-HT2C</term><term>Serotonin</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term><term>Parkinson Disease</term><term>Schizophrenia</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term><term>Schizophrenia</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Serotonin2C (5-HT2C) receptors are expressed in the basal ganglia, a group of subcortical structures involved in the control of motor behaviour, mood and cognition. These receptors are mediating the effects of 5-HT throughout different brain areas via projections originating from midbrain raphe nuclei. A growing interest has been focusing on the function of 5-HT2C receptors in the basal ganglia because they may be involved in various diseases of basal ganglia function notably those associated with chronic impairment of dopaminergic transmission. 5-HT2C receptors act on numerous types of neurons in the basal ganglia, including dopaminergic, GABAergic, glutamatergic or cholinergic cells. Perhaps inherent to their peculiar molecular properties, the modality of controls exerted by 5-HT2C receptors over these cell populations can be phasic, tonic (dependent on the 5-HT tone) or constitutive (a spontaneous activity without the presence of the ligand). These controls are functionally organized in the basal ganglia: they are mainly localized in the input structures and preferentially distributed in the limbic/associative territories of the basal ganglia. The nature of these controls is modified in neuropsychiatric conditions such as Parkinson's disease, tardive dyskinesia or addiction. Most of the available data indicate that the function of 5-HT2C receptor is enhanced in cases of chronic alterations of dopamine neurotransmission. The review illustrates that 5-HT2C receptors play a role in maintaining continuous controls over the basal ganglia via multiple diverse actions. We will discuss their interest for treatments aimed at ameliorating current pharmacotherapies in schizophrenia, Parkinson's disease or drugs abuse.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23615975</PMID><DateCreated><Year>2013</Year><Month>10</Month><Day>01</Day></DateCreated><DateCompleted><Year>2014</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1106</ISSN><JournalIssue CitedMedium="Internet"><Volume>230</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Experimental brain research</Title><ISOAbbreviation>Exp Brain Res</ISOAbbreviation></Journal><ArticleTitle>Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.</ArticleTitle><Pagination><MedlinePgn>477-511</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00221-013-3508-2</ELocationID><Abstract><AbstractText>Serotonin2C (5-HT2C) receptors are expressed in the basal ganglia, a group of subcortical structures involved in the control of motor behaviour, mood and cognition. These receptors are mediating the effects of 5-HT throughout different brain areas via projections originating from midbrain raphe nuclei. A growing interest has been focusing on the function of 5-HT2C receptors in the basal ganglia because they may be involved in various diseases of basal ganglia function notably those associated with chronic impairment of dopaminergic transmission. 5-HT2C receptors act on numerous types of neurons in the basal ganglia, including dopaminergic, GABAergic, glutamatergic or cholinergic cells. Perhaps inherent to their peculiar molecular properties, the modality of controls exerted by 5-HT2C receptors over these cell populations can be phasic, tonic (dependent on the 5-HT tone) or constitutive (a spontaneous activity without the presence of the ligand). These controls are functionally organized in the basal ganglia: they are mainly localized in the input structures and preferentially distributed in the limbic/associative territories of the basal ganglia. The nature of these controls is modified in neuropsychiatric conditions such as Parkinson's disease, tardive dyskinesia or addiction. Most of the available data indicate that the function of 5-HT2C receptor is enhanced in cases of chronic alterations of dopamine neurotransmission. The review illustrates that 5-HT2C receptors play a role in maintaining continuous controls over the basal ganglia via multiple diverse actions. We will discuss their interest for treatments aimed at ameliorating current pharmacotherapies in schizophrenia, Parkinson's disease or drugs abuse.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Deurwaerdère</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Bordeaux Cedex, France, deurwaer@u-bordeaux2.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagière</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bosc</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Navailles</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Exp Brain Res</MedlineTA><NlmUniqueID>0043312</NlmUniqueID><ISSNLinking>0014-4819</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044405">Receptor, Serotonin, 5-HT2C</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044405" MajorTopicYN="N">Receptor, Serotonin, 5-HT2C</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23615975</ArticleId><ArticleId IdType="doi">10.1007/s00221-013-3508-2</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000678 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000678 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23615975
|texte= Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23615975" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |